Article Information
History
- July 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Eman Zeyad I. Elmekaty, PharmD1,*,
- Aya Maklad, PharmD2,
- Rawan Abouelhassan, PharmD2,
- Waqar Munir, CABM1,
- Mohamed Izham Mohamed Ibrahim, PhD3,
- Arun Nair, MBBS MD1,
- Rim Alibrahim, PharmD1,
- Fatima Iqbal, PharmD1,
- Ahmad Al Bishawi, MD1,
- Alaaeldin Abdelmajid, MD1,
- Mohamed Aboukamar, CABM1,
- Mohammed Abu Khattab, CABM1,
- Hussam Al Soub, CABM1 and
- Muna Al Maslamani, MBBS MSc-HCM4
- 1Communicable Diseases Center, Hamad Medical Corporation, PO BOX 3050, Doha, Qatar
- 2College of Pharmacy, QU Health, Qatar University, PO BOX 2713, Doha, Qatar
- 3Clinical Pharmacy & Practice Department, College of Pharmacy, QU Health, Qatar University, PO Box: 2713, Doha, Qatar
- 4Medical Director of Communicable Diseases Center, Hamad Medical Corporation, PO BOX 3050, Doha, Qatar
- ↵*Corresponding Author
Dr. Eman Zeyad Ibrahim Elmekaty, BSc (Pharm), PharmD, RPh, SIDP/ASCP, BCIDP, Clinical Pharmacist - Infectious Disease, Communicable Disease Center – HMC, Tel: (+974) 40254259, P.O. Box 3050 Doha, Qatar, Eelmekaty{at}hamad.qa
Posted July 06, 2022.
Efficacy of Anakinra in the Management of Patients with COVID-19 Infection: A Randomized Clinical Trial
